i Predict Breast cancer Assays The i Predict

i. Predict Breast cancer Assays The i. Predict Breast cancer assay helps you find an answer i. Predict Recurrences Score result assesses the benefit of chemotherapy and the likelihood of breast cancer recurrence

DISCLAIMER The content of this presentation is strictly private, confidential and should not be copied, distributed or reproduced in whole or in part, nor passed to any third party!

Do all Breast cancer patients benefit from chemotherapy? Landmark NSABP B-20 trial of 651 estrogen-positive (ER-positive), nodenegative breast cancer patients found § The addition of chemotherapy provided only a 4% benefit, measured as the proportion of patients free distant recurrence at 10 years Breast Cancer Assay is the only test that provides patients with an individual score validated to predict chemotherapy benefit and likelihood of distant recurrence.

The Prognostic utility of the Breast Cancer Recurrences Assay More than half patient tested had low recurrence score and avoided chemotherapy

Adding critical information to your treatment decision Patients with high ER score (and low recurrence values) saw the largest benefit from treatment with tamoxifen. 9

The Predictive utility of the Breast Cancer Recurrences Assay Low and intermediate risk patients had very limited benefit by addition of chemotherapy

Predict the benefit of chemotherapy in node-negative patients High risk patients benefit the most by addition of Chemotherapy

Provides additional insight over age & tumor size to guide treatment decision Patients Younger with patients large can tumours have can low have recurrence low recurrence score value. 1 Patients Older patients with smaller can have tumours high recurrence can have high score recurrence value. 1 score value. 1

Providing independent, significant data beyond traditional measures § Significant proportions of highgrade tumors have low recurrence scores values § Even low-grade tumors can have high recurrence score values Nearly 1 in 3 adjuvant treatment recommendations based on the recurrence score results in decision impact study

Providing independent recurrence risk information across a biologic continuum

Predict the benefit of chemotherapy in node-positive patients • For 33% patients tested with Oncotype, their treatment was changed from chemotherapy plus hormonal therapy to hormonal therapy alone. • For 9. 4% of patients tested with Oncotype, their treatment was changed from hormonal therapy alone to chemotherapy plus hormonal therapy.

NCCN recommends Oncotype in broad range of patients for prognostic & predictive information i. Predict Breast Cancer Assay § Analyzes the expression of 30 gens § Predicts chemotherapy benefit § Indicates the 10 year risk of distant recurrence § Eligible ER-Positive breast cancer patients Oncotype Breast Cancer Assay is the only multigene expression assay incorporatred in both the ASCO and NCCN guideline.